Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma

For 20 years, the standard therapy for inoperable locally advanced non-small cell lung carcinoma (LA-NSCLC) was definitive concurrent chemotherapy and photon radiation therapy (RT). In 2018, based on the findings from the landmark PACIFIC trial demonstrating an overall survival (OS) benefit from adding adjuvant durvalumab to standard chemotherapy and photon RT, the US Food and Drug Administration approved the adjuvant ICI durvalumab as a new standard of care in such cases.[1,2] Nevertheless, RT-related cardiac and pulmonary toxicity remains a significant source of morbidity and mortality in LA-NSCLC survivors,[3,4] and radiation-induced lymphopenia (RIL) attenuates the effectiveness of immune checkpoint inhibitors for these patients.

Source: Radiotherapy and Oncology - February 2, 2024 Category: Radiology Authors: Kelsey L. Corrigan, Ting Xu, Yuki Sasaki, Ruitao Lin, Aileen B. Chen, James W. Welsh, Steven H. Lin, Joe Y. Chang, Matthew S. Ning, Saumil Gandhi, Michael S. O'Reilly, Carl M. Gay, Mehmet Altan, Charles Lu, Tina Cascone, Efstratios Koutroumpakis, Ajay She Tags: Original Article Source Type: research